These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Effect of nicotine lozenges on affective smoking withdrawal symptoms: secondary analysis of a randomized, double-blind, placebo-controlled clinical trial. Shiffman S Clin Ther; 2008 Aug; 30(8):1461-75. PubMed ID: 18803988 [TBL] [Abstract][Full Text] [Related]
25. New mechanisms and perspectives in nicotine withdrawal. Jackson KJ; Muldoon PP; De Biasi M; Damaj MI Neuropharmacology; 2015 Sep; 96(Pt B):223-34. PubMed ID: 25433149 [TBL] [Abstract][Full Text] [Related]
27. Δ Xi ZX; Muldoon P; Wang XF; Bi GH; Damaj MI; Lichtman AH; Pertwee RG; Gardner EL Br J Pharmacol; 2019 Dec; 176(24):4773-4784. PubMed ID: 31454413 [TBL] [Abstract][Full Text] [Related]
28. Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. Berrendero F; Kieffer BL; Maldonado R J Neurosci; 2002 Dec; 22(24):10935-40. PubMed ID: 12486188 [TBL] [Abstract][Full Text] [Related]
29. Targeting Dopaminergic System for Treating Nicotine Dependence. Abuhamdah S; Khalil A; Sari Y Cent Nerv Syst Agents Med Chem; 2016; 16(2):137-42. PubMed ID: 26530056 [TBL] [Abstract][Full Text] [Related]
30. Endogenous opioids and addiction to alcohol and other drugs of abuse. Gianoulakis C Curr Top Med Chem; 2004; 4(1):39-50. PubMed ID: 14754375 [TBL] [Abstract][Full Text] [Related]
31. Blockade of nicotinic acetylcholine or dopamine D1-like receptors in the central nucleus of the amygdala or the bed nucleus of the stria terminalis does not precipitate nicotine withdrawal in nicotine-dependent rats. Jonkman S; Markou A Neurosci Lett; 2006 May; 400(1-2):140-5. PubMed ID: 16563623 [TBL] [Abstract][Full Text] [Related]
34. Genetic variation in mu-opioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial. Ray R; Jepson C; Wileyto EP; Dahl JP; Patterson F; Rukstalis M; Pinto A; Berrettini W; Lerman C Nicotine Tob Res; 2007 Nov; 9(11):1237-41. PubMed ID: 17978999 [TBL] [Abstract][Full Text] [Related]
35. Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans. Scott DJ; Domino EF; Heitzeg MM; Koeppe RA; Ni L; Guthrie S; Zubieta JK Neuropsychopharmacology; 2007 Feb; 32(2):450-7. PubMed ID: 17091130 [TBL] [Abstract][Full Text] [Related]
36. Are Pharmacotherapies Ineffective in Opioid-Dependent Smokers? Reflections on the Scientific Literature and Future Directions. Miller ME; Sigmon SC Nicotine Tob Res; 2015 Aug; 17(8):955-9. PubMed ID: 26180219 [TBL] [Abstract][Full Text] [Related]
38. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Fagerström K; Balfour DJ Expert Opin Investig Drugs; 2006 Feb; 15(2):107-16. PubMed ID: 16433591 [TBL] [Abstract][Full Text] [Related]
39. Effects of pharmacological manipulation of the kappa opioid receptors on the aversive effects of nicotine. Ward M; Norman H; D'Souza MS Behav Brain Res; 2018 Feb; 338():56-65. PubMed ID: 29037662 [TBL] [Abstract][Full Text] [Related]
40. Historical Review: Opiate Addiction and Opioid Receptors. Wang S Cell Transplant; 2019 Mar; 28(3):233-238. PubMed ID: 30419763 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]